retatrutide ly3437943 triple agonist glp-1 gip glucagon Research Peptide Australia | GLP-1/GIP/Glucagon glp 1 gip triple agonist
Description
Although most of the studies reported an association between GLP-1 RA and increased residual gastric contents, evidence linking these medications to a statistically significant rise in regurgitation or aspiration events remains highly inconsistent
Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results
Gastrointestinal symptoms were the most common side effects
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors
GLP-1 is a hormone that the gut produces after eating to regulate blood sugar, slow digestion and manage hunger
